Localized scleroderma in a woman irradiated at two sites for endometrial and breast carcinoma: a case history and a review of the literature.

Localized scleroderma is an uncommon side-effect of radiotherapy. We report a unique case with multiple asynchronous primary malignant tumors, which developed localized scleroderma after radiotherapy. A 67-year-old healthy woman received external irradiation for endometrial cancer.

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

Background: Owing to the wide spread perception of a possible benefit from paclitaxel in the second-line situation the Nordic Gynecologic Oncology Group (NGOG) conducted two prospective phase II studies of paclitaxel single agent treatment (175 mg/m2, three-hour i.v. infusion with standard pre-medication every third week) in patients with relapsing or progressing epithelial ovarian cancer following platinum.

Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group.

In a controlled prospective randomized study the regimen doxorubicin (A) 40 mg/m2 + melphalan (M) 0.4 mg/kg was compared with A + M + cisplatin (C) 50 mg/m2 given every four weeks in advanced ovarian cancer, FIGO stage III or IV and with serous or anaplastic histology. From 1981 to 1983, 300 patients entered the study and 295 patients were evaluable for response, toxicity and long-term survival.

Insufficiency fractures of the sacrum after radiotherapy for gynaecological malignancy.

An entity is described which is characterized by low back pain and increased radionuclide uptake in the sacrum at bone scintigraphy in postmenopausal women having received radiotherapy towards the pelvis because of gynaecological malignancy. The findings stimulate bone metastases, but are in all likelihood caused by insufficiency fractures of the sacrum promoted by bone weakness induced by postmenopausal osteoporosis and radiotherapy combined. The increased radionuclide activity has a characteristic appearance which in the fully developed fracture acquires the shape of an 'H'.

Dysgerminoma. The Radiumhemmet series 1927-1984.

Dysgerminoma is a rare, highly radiosensitive, malignant germ cell tumor occurring in young females. At Radiumhemmet, Stockholm, Sweden, from 1927 to 1984, 60 patients with histologically confirmed pure dysgerminoma were treated. Primary treatment was surgery followed by radiotherapy.

Radiation dose and breast cancer risk in patients treated for cancer of the cervix.

The relationship between breast cancer and radiation treatment for cervical cancer was evaluated in an international study of 953 women who subsequently developed breast cancer and 1,806 matched controls. Radiation doses to the breast (average 0.31 Gy) and ovaries (average 32 Gy) were reconstructed for exposed subjects on the basis of their original radiotherapy records.

Radiation dose and second cancer risk in patients treated for cancer of the cervix.

The risk of cancer associated with a broad range of organ doses was estimated in an international study of women with cervical cancer. Among 150,000 patients reported to one of 19 population-based cancer registries or treated in any of 20 oncology clinics, 4188 women with second cancers and 6880 matched controls were selected for detailed study. Radiation doses for selected organs were reconstructed for each patient on the basis of her original radiotherapy records.

Evaluation of screening for cervical cancer in Sweden: trends in incidence and mortality 1958-1980.

Papanicolaou screening for cancer of the uterine cervix was introduced in Sweden in the late 1950's. Screening programmes covering the age groups 30-49 years were organized in various countries between 1965 and 1973. The approximate number of smears rose from 100 000 in 1960 to one million in 1970, in a female population of four million.

Combined morphologic and cytochemical grading of serous ovarian tumors.

The potentiality of DNA analysis to complement morphologic evaluation in classifying serous ovarian tumors as adenoma, borderline malignancy, or invasive adenocarcinoma was investigated in a series of 54 tumors. The DNA analyses were performed on histologic tumor sections. The primary diagnoses were borderline tumor in 24 cases and invasive adenocarcinoma in 30 (World Health Organization classification).

Prognostic significance of nuclear DNA content in serous ovarian tumors.

Specimens from 73 serous ovarian cancers were examined with respect to DNA content of the tumor cells. The prognostic value of DNA analysis, as reflected in patient survival, was retrospectively compared with that of conventional histological assessment of cancer. DNA in individual tumor cells was measured in sections from the original paraffin-embedded specimens.

Blood group distribution in women with ovarian cancer.

The distribution of ABO blood groups and Rh factor was studied in 1930 patients treated at Radiumhemmet for ovarian tumour in the period 1958-1973. The tumour was malignant in 1732 cases and of borderline malignancy in 198. A predominance of blood group A at the expense of group O emerged when the series was compared with findings in 24 120 healthy conscripts.

Long-term follow-up and prognostic factors in ovarian carcinoma. The radiumhemmet series 1958 to 1973.

Between 1958 and 1973, 2412 women with epithelial ovarian carcinoma were treated at Radiumhemmet. Of these tumors, 14.5 per cent were of borderline malignancy.

Carcinoma of the uterine cervix. Incidence and mortality in the Stockholm-Gotland region.

During the years 1958 to 1978, 3 607 women with invasive cervical carcinoma were reported to the Stockholm-Gotland Tumour Registry. A decreased incidence rate was found among women born 1910 to 1930 when comparing the 5-year cumulative incidence rate for the different birth cohorts at the same age. A reduced mortality was demonstrated in the same way.

Postmenopausal bone mineral loss after treatment for malignant gynaecologic tumours.

Bone mineral content after treatment for malignant gynaecologic tumours was examined in women of fertile age. The treatment given was intracavitary radium applications followed by bilateral oophorectomy. In women who received oestrogen substitution the bone mineral content increased by one per cent a year, whereas nonsubstituted women lost 3 per cent of their initial bone mineral content per year.

Granulosa cell tumors: A comparison of survival in patients and matched controls.

The survival rate in a group of 153 patients with granulosa cell tumor of the ovary was compared to that in a control group of 306 women who were matched with respect to age and geographical location. The mean follow-up time was 15.0 years.

Theca-cell tumors. Clinical features and prognosis.

During the period 1923 to 1972, 62 women with theca-cell tumors were treated at Radiumhemmet. The mean age at diagnosis was 59.5 years.

Granulosa- and theca-cell tumors. Incidence and occurrence of second primary tumors.

An analysis of 936 women with granulosa- and theca-cell tumors reported to the Swedish Cancer Registry between 1958 and 1972 showed crude annual incidence rates for these lesions of 0.72 and 0.74, respectively, pre 100 000 of the female population, unchanged during the period.

Granulosa-cell and theca-cell tumors. The clinical picture and long-term outcome for the Radiumhemmet series.

Over the period 1923--72 a total of 305 patients with granulosa-cell, theca-cell tumor and mixed tumor were seen at Radiumhemmet. The commonest symptom was abnormal uterine bleeding. Twenty-three per cent of married women were nulliparous.